NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 11/6/2026 02:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Kaleido Biosciences Stock (NASDAQ:KLDO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kaleido Biosciences alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.20Volume4,496 shsAverage Volume2,410 shsMarket Capitalization$4.26 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kaleido Biosciences, Inc. was a clinical-stage biotechnology company focused on developing therapies designed to influence the human microbiome. Its approach centered on Microbiome Metabolic Therapies, which used synthetic glycans intended to selectively feed beneficial bacteria and promote the production of metabolites associated with improved health. The company investigated its platform across several disease areas, including metabolic disorders, immune-related conditions, infectious diseases and cancer. Its development programs included KB109, which was studied in conditions such as COVID-19 and cancer, as well as programs targeting disorders involving ammonia metabolism and phenylalanine processing. Founded in 2015 and headquartered in Lexington, Massachusetts, Kaleido became a publicly traded company on the Nasdaq in 2019. The company later discontinued clinical development and moved to wind down its operations following a strategic review. Accordingly, Kaleido Biosciences is primarily of historical interest rather than an active operating biotechnology company.AI Generated. May Contain Errors. Read More Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLDO Stock News HeadlinesKaleido Biosciences Insider Trading Activity | OTC:KLDO | BenzingaApril 20, 2026 | benzinga.comKaleido Biosciences Inc.February 18, 2026 | marketwatch.comMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 8 at 1:00 AM | Porter & Company (Ad)Kaleido Biosciences Inc (KLDO)April 10, 2025 | uk.investing.comSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Fourth Straight YearDecember 11, 2024 | finance.yahoo.comBICS, Cellusys, Comfone, Mobileum, Syniverse, Telefónica Global Solutions & TOMIA MACH Named Champion Roaming Vendors by Kaleido IntelligenceNovember 25, 2024 | markets.businessinsider.comKaleido Biosciences (OTC:KLDO) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comKaleido announces the appointment of RBC Investor Services as the new custodian of its scholarship plansOctober 1, 2024 | ca.finance.yahoo.comSee More Headlines KLDO Stock Analysis - Frequently Asked Questions How have KLDO shares performed this year? Kaleido Biosciences' stock was trading at $0.0001 at the beginning of 2026. Since then, KLDO stock has increased by 0.0% and is now trading at $0.0001. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.54) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.54). The company had revenue of $100 thousand for the quarter, compared to the consensus estimate of $250 thousand. When did Kaleido Biosciences IPO? Kaleido Biosciences (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Precision BioSciences (DTIL), Editas Medicine (EDIT), LogicBio Therapeutics (LOGC), Alector (ALEC), Black Diamond Therapeutics (BDTX), Gossamer Bio (GOSS) and HOOKIPA Pharma (HOOK). Company Calendar Today11/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:KLDO CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$4.26 thousand OptionableNot Optionable Beta-0.06 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:KLDO) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredA monthly income idea that does not require selling sharesA $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
